Attitudes about pharmacogenomic testing vary by healthcare specialty
Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx testing and its perceived utility on web-based surveys before and after genetics education. Primary quantitative analyses compared primary care providers (PCPs) to specialty providers at both timepoints. Results: PCPs were more likely than specialty care providers to rate PGx testing as useful at both timepoints. Education increased comfort ordering PGx tests, with larger improvements among PCPs than specialty providers. Over 90% of cardiology and internal medicine providers rated PGx testing as useful at pre- and post-education. Conclusion: PCPs overwhelmingly perceive PGx to be useful, and provider education is particularly effective for improving PCPs' confidence. Education for all specialties will be essential to ensure appropriate integration into routine practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 10 vom: 17. Juli, Seite 539-549 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Preys, Charlene L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.08.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359587720 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359587720 | ||
| 003 | DE-627 | ||
| 005 | 20231226081210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359587720 | ||
| 035 | |a (NLM)37458095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Preys, Charlene L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Attitudes about pharmacogenomic testing vary by healthcare specialty |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx testing and its perceived utility on web-based surveys before and after genetics education. Primary quantitative analyses compared primary care providers (PCPs) to specialty providers at both timepoints. Results: PCPs were more likely than specialty care providers to rate PGx testing as useful at both timepoints. Education increased comfort ordering PGx tests, with larger improvements among PCPs than specialty providers. Over 90% of cardiology and internal medicine providers rated PGx testing as useful at pre- and post-education. Conclusion: PCPs overwhelmingly perceive PGx to be useful, and provider education is particularly effective for improving PCPs' confidence. Education for all specialties will be essential to ensure appropriate integration into routine practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a attitude | |
| 650 | 4 | |a clinical | |
| 650 | 4 | |a decision support systems | |
| 650 | 4 | |a family practice | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a health education | |
| 650 | 4 | |a health personnel | |
| 650 | 4 | |a medicine | |
| 650 | 4 | |a pharmacogenomic testing | |
| 650 | 4 | |a physicians | |
| 650 | 4 | |a testing | |
| 700 | 1 | |a Blout Zawatsky, Carrie L |e verfasserin |4 aut | |
| 700 | 1 | |a Massmann, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Heukelom, Joel Van |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Hajek, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Hickingbotham, Madison R |e verfasserin |4 aut | |
| 700 | 1 | |a Zoltick, Emilie S |e verfasserin |4 aut | |
| 700 | 1 | |a Schultz, April |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Kurt D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 10 vom: 17. Juli, Seite 539-549 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:10 |g day:17 |g month:07 |g pages:539-549 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 10 |b 17 |c 07 |h 539-549 | ||